Evaluating Dupilumab for Early Asthma Control to Achieve Remission in Adults with Moderate Type-2 Inflammatory Asthma
Led by Université de Sherbrooke · Updated on 2026-10-02
150
Participants Needed
5
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether early treatment with the asthma medication dupilumab can help adults with moderate asthma achieve complete control of their condition, called remission. This study focuses on people aged 18 to 79 who have experienced at least one asthma attack requiring steroid pills in the past two years and have high markers of inflammation, but do not yet have severe asthma. The goal is to see if starting dupilumab earlier can prevent attacks and lung damage compared to current treatments that begin after asthma worsens.
Participants receive either dupilumab or placebo injections every two weeks for one year, in addition to their regular asthma medications. The study is double-blind, so neither participants nor doctors know who receives the real medication. The treatment period tests if dupilumab increases the chances of remission compared to standard inhaled steroid adjustments. The trial is conducted in Canada, the United Kingdom, and Australia with 150 participants.
During the study, participants attend clinic visits every three months for breathing tests, questionnaires, and safety monitoring. Researchers measure lung function, asthma attacks, medication use, symptoms, quality of life, and inflammatory markers over the year. The main outcome is a win ratio based on remission criteria from week 4 to week 56. Safety and treatment effects are closely followed throughout the study period.
CONDITIONS
Brief Title
A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Physician-diagnosed asthma for 6 months or more with documented airflow variability
Elevated type-2 inflammatory markers: blood eosinophils ≥ 0.3 ×10⁹/L and exhaled nitric oxide ≥ 35 ppb at screening
At least one asthma attack in the past 2 years requiring systemic corticosteroids or emergency/hospital visit
Stable use of at least medium-dose inhaled corticosteroids for at least 3 months
Presence of one or more risk factors: uncontrolled symptoms (ACQ5 ≥ 1.5), impaired lung function (post-bronchodilator FEV1 ≤ 80% predicted), high-dose ICS use, or recent severe asthma attack
Female participants must not be pregnant or breastfeeding and follow contraception requirements if of childbearing potential
Able to provide signed informed consent
You will not qualify if you...
Use of systemic corticosteroids less than 1 month before screening or on maintenance systemic steroids
Current tobacco smoker or stopped smoking less than 6 months ago
Ex-smoker with more than 10 pack-years and abnormal lung function (FEV1/FVC below normal)
Documented poor adherence to inhaled corticosteroids (less than 75% of prescribed dose in past year)
Significant inhaler technique problems
Contraindication to study drug
Immunological conditions or medications affecting inflammation
Other significant lung diseases like fibrosis, sarcoidosis, bronchiectasis, COPD
Severe illness or immunodeficiency affecting participation
Active cancer or history of cancer within 5 years (except certain skin or cervical conditions)
Previous use of monoclonal antibody therapy for asthma or investigational drugs recently
Eligible for dupilumab under local licensed uses for other conditions
Recent live vaccine treatment (within 4 weeks)
Use of prohibited medications
Current helminth infection
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening visit
Treatment
Duration - 1 year
Participants receive dupilumab or placebo injections every two weeks alongside their regular asthma medications.
Clinic visits every 3 months for breathing tests, questionnaires, and safety monitoring
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Evaluating Dupilumab for Early Asthma Control to Achieve Remission in Adults with Moderate Type-2 Inflammatory Asthma
Study of Energy Recovery Ventilators and Portable Air Cleaners to Improve Indoor Air Quality and Asthma in Children and Adults in Low-Income Dallas-Fort Worth Homes
Improving Asthma Specialist Follow-Up After Emergency Room Visits Using Telehealth Compared to Standard Referral
Study of Air Quality Index Information Added to Asthma Action Plans to Improve Asthma in Children Ages 8 to 17
Study of the Walsh Asthma Self-Management Program for Adults with Asthma in Primary Care
Evaluating Its Usefulness and Ease of Delivery by Nurses
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Protocol for a multinational, investigator-initiated, parallel-group, randomized, double-blind, placebo-controlled phase 3b superiority trial assessing the effect of dupilumab on inducing clinical remission outcomes in at-risk type-2 inflammatory asthma (HOTHOT).
Simon Couillard, Nayia Petousi, Sanjay Ramakrishnan...